Aukera builds a discovery engine that allows designing new classes of drugs to selectively target different branches of the mTOR pathway. The lead program selectively targets mTOR complex 1 to treat rare diseases, cancer, and neurodegenerative diseases, and uniquely addresses unmet medical needs.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business